Frequently asked questions
)
What is cutaquig®?1
Cutaquig® is a high purity 16,5% human normal immunoglobulin solution for subcutaenous infusion (SCIg) and is the result of more than 40 years of Octapharma fractionation experience using state-of-the-art manufacturing processes. Please click here to learn more about cutaquig®.
What is cutaquig® indicated for?1
Cutaquig® has approved indications for IgG replacement therapy in primary immunodeficiency (PID) and secondary immunodeficiency (SID). Please refer to this page to learn more.
Can my patients self-administer cutaquig®?1
Cutaquig® is a self-administered immunoglobulin therapy for PID and SID. Patients can learn to easily give themselves cutaquig® with training from a healthcare professional. After patients have gone through training and have successfully self-administered in front of a healthcare professional, they can self-administer cutaquig®.
If patients would like a helpful reminder tool after they have been trained to self-infuse cutaquig®, or if they would like a refresher later on, patients can follow easy instructions detailed in the self-administration guide.
It might be a good idea to periodically ask your patients about their self-administration technique, especially if their infusion regimen has recently changed. See resources for managing therapy for more information.
How do I mitigate infusion site reactions?2
Tailoring treatment experiences to the needs of the individual may improve treatment adherence and quality of life for patients with immunodeficiency diseases who often rely on long-term or lifelong treatment. See here some approaches to mitigate local reactions.
What are the contraindications for receiving treatment with cutaquig®?1
Contraindications include hypersensitivity to the active substance or any of the excipients. Do not infuse intravenously. No intramuscular administration in case of severe thrombocytopenia or other disorders of haemostasis. Please always refer to the Summary of Product Characteristics for full prescribing information. Section 4.3 of the Summary of product Characteristics describes the possible contraindications with cutaquig®.
What possible drug interactions with cutaquig® have been identified?1
Possible drug interactions may occur with live attenuated virus vaccines. Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months (up to 1 year in case of measles) the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. Please always refer to the Summary of product Characteristics for full prescribing information. Section 4.5 of the Summary of Product Characteristics describes interactions with other medicinal products and other forms of interactions.
What is the stabilizer of cutaquig®?1
Maltose is used as stabilizer.
What is the infusion rate of cutaquig®?1
It is recommended to use an initial administration rate of 15 mL/hour/site for patients naive on SCIg therapy. For patients already on SCIG therapy and switching to cutaquig® it is recommended to use previously used administration rates for the initial infusions. For subsequent infusions, if well tolerated, the infusion rate can be gradually increased by approximately 10 mL/hour/site every 2-4 weeks in adults (≥ 40 kg) and up to 10 mL/hour/site every 4 weeks for paediatrics (<40 kg). Thereafter, if the patient tolerates the initial infusions at the full dose per site and maximum rate, an increase in the infusion rate of successive infusions may be considered until reaching a maximum flow rate of 67.5 mL/hour/site for adults and 25 mL/hour/site for paediatrics. More than one infusion device can be used simultaneously. Please always refer to the Summary of Product Characteristics for full prescribing information.
How long does it take to infuse cutaquig®?1
The time taken to infuse cutaquig® depends on the specified infusion rate, the dose, and the weight of the patient. It is usually highly patient specific. Please refer to our dosing calculator page for more information on infusion rates and dosing regimens. Please always refer to the Summary of Product Characteristics for full prescribing information.
References:
Cutaquig® European Summary of Product Characteristics. November 2023.
Epland, K. et al., A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy, Asthma & Clinical Immunology, 2022. 18:87.
This is an international website for cutaquig® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website www.octapharma.com.
